Just as GlaxoSmithKline launches an assault at Gilead Sciences’ HIV business in the treatment realm, it’s also targeting the prevention market with new data backing a more convenient alternative to existing offerings.
Gilead’s Truvada won the first FDA nod in 2012 to reduce the risk of HIV infection as a PrEP regimen. Now, GSK has shown its long-acting injectable cabotegravir, given every two months, worked just as well at fending off the virus as Gilead’s daily pill.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,